Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues.
Share: email Subscribe
Weekly Top Stories Wed, 07 Apr 2021
We have 28 articles this week. #Amgen Buys Rodeo for $721 Million. #Aspen Surgical Acquires #BlueMedMedicalSupplies. #CharlesRiverLaboratories Acquires #Retrogenix. #BauschHealth Agrees To Sell #AmounPharmaceuticals. #COVAXX and #UnitedNeuroscience Are Now #Vaxxinity. #Amgen to Acquire #RodeoTherapeutics Corporation. #Ro Nabs $500M to Strengthen Vertically Integrated Primary Care Platform. #AKASA Raises $60M to Automate Revenue Cycle Operations for Health Systems. #AppliedVR Lands $29M for VR Platform to Treat Chronic Pain. #Mastercard, #b.well Team Up on Digital Health Patient ID Verification for Interoperability. #AbCellera and #GileadSciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration. #AmericanRheumatologyNetwork (ARN) and #TrioHealth (Trio) form #ARNClinicalResearch, a Tech-Enabled Solution to Accelerate Clinical Trials
Editor's Choice
1. 
2021 Pipeline Insights Into Scleroderma – Key Players Include Corbus Pharmaceuticals, Gesynta Pharma and Formation Biologics
2. 
Investors Pour $7.1B Into Digital Health Investments During Q1 2021
3. 
Digital Health Completes a Record-breaking First Quarter Driven By Mega Deals
4. 
Prostate Cancer Pipeline Insights: Comprehensive Analysis of Key Emerging Therapies and Pharmaceutical Companies
5. 
Trending Report on E Pharma Market 2021-2026 Business Outlook
Top 10 M&A Transactions
6. 
In Second Acquisition This Month, Amgen Buys Rodeo for $721 Million
7. 
Charles River Laboratories Acquires Retrogenix
8. 
Bausch Health Agrees to Sell Amoun Pharmaceuticals
9. 
COVAXX and United Neuroscience are Now Vaxxinity
10. 
Amgen to Acquire Rodeo Therapeutics Corporation
11. 
Charles River Laboratories Completes the Acquisition of Cognate BioServices
12. 
KD Pharma Acquires Rohner AG Manufacturing Assets
13. 
Merck Completes Acquisition of Pandion Therapeutics
14. 
Eloxx Pharmaceuticals Acquires Zikani Therapeutics
15. 
Revelstoke’s Carrus Acquires Archetype Innovations
Top 3 Venture Funding
16. 
Ro Nabs $500M to Strengthen Vertically Integrated Primary Care Platform
17. 
AKASA Raises $60M to Automate Revenue Cycle Operations for Health Systems
18. 
AppliedVR Lands $29M for VR Platform to Treat Chronic Pain
Top 4 Partnerships Announcements
19. 
Mastercard, B.well Team up on Digital Health Patient ID Verification for Interoperability
20. 
AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration
21. 
EGenesis Expands Research Collaboration with Leading Academic Medical Center
22. 
American Rheumatology Network (ARN) and Trio Health (Trio) Form ARN Clinical Research, a Tech-Enabled Solution to Accelerate Clinical Trials
Read More Corporate Development and M&A Activity
Get Featured: Send us your article or blog and we will feature it on our publication, reach over thousands of executives. Click Here.
Editor: Ed Francis

Ed has more than 25 years of management consulting experience and currently is the Global Managing Partner for Infosys Consulting Health and Life Sciences business guiding some of the industry's most prominent health and life sciences organizations through complex transformations.

If you need help with your complex transformation whether it be M&A, digital, or strategic cost reduction or need to bring more innovation into your business strategy Ed can be contacted at Edward.Francis@infosys.com and +1-847-910-6073

Or connect with him at

OTHER ADVISORIES

Health Plan Hospital IT
IT GovHealth
Retail POP Health
Ageing Life Sciences

Advertise with us

We Reach Half Million Decision Makers in:
Healthcare · IT · Retail · Industrial
Advertise with us and reach the right audience.
advertise@distilnfo.com

Contact Us

5760 Legacy Dr, B3-405,
Plano TX 75024
+1 469-270-3311

DistilINFO Publications

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you - saving time and keeping you up to date on your interest areas.

You are receiving this newsletter because you are subscribed to one or more DistilINFO Publications Newsletter/s. If you feel this email was sent by mistake or you want to opt out, you can unsubscribe.

View in browser | Advertise | Contact Us